Published in Clin Exp Metastasis on December 05, 2007
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol (2010) 2.94
Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer (2010) 1.93
Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol (2009) 1.53
Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenetics (2010) 1.33
Epigenetic diet: impact on the epigenome and cancer. Epigenomics (2011) 1.33
Circadian rhythm disruption in cancer biology. Mol Med (2012) 1.31
Trichostatin a inhibits corneal haze in vitro and in vivo. Invest Ophthalmol Vis Sci (2009) 1.31
Histone deacetylases play a major role in the transcriptional regulation of the Plasmodium falciparum life cycle. PLoS Pathog (2010) 1.27
The role of histone deacetylases in prostate cancer. Epigenetics (2008) 1.21
Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis (2013) 1.17
Post-translational modification and regulation of actin. Curr Opin Cell Biol (2012) 1.10
HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett (2010) 1.06
Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2. Genes Dev (2011) 1.03
A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors. J Biol Chem (2010) 1.02
Inhibition of histone deacetylase activity in reduced oxygen environment enhances the osteogenesis of mouse adipose-derived stromal cells. Tissue Eng Part A (2009) 1.01
Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther (2008) 0.99
Epigenetic alterations in ultraviolet radiation-induced skin carcinogenesis: interaction of bioactive dietary components on epigenetic targets. Photochem Photobiol (2011) 0.95
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells. Mol Cancer Ther (2010) 0.93
Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol (2012) 0.90
Nitric oxide and histone deacetylases: A new relationship between old molecules. Commun Integr Biol (2009) 0.90
Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis. Am J Respir Cell Mol Biol (2012) 0.89
Epigenomics of ovarian cancer and its chemoprevention. Front Genet (2011) 0.89
"Curcumin, the King of Spices": Epigenetic Regulatory Mechanisms in the Prevention of Cancer, Neurological, and Inflammatory Diseases. Curr Pharmacol Rep (2015) 0.88
Plant phytochemicals as epigenetic modulators: role in cancer chemoprevention. AAPS J (2013) 0.86
Epigenetics of neurological cancers. Future Oncol (2009) 0.85
LAceP: lysine acetylation site prediction using logistic regression classifiers. PLoS One (2014) 0.84
Diet, the gut microbiome, and epigenetics. Cancer J (2014) 0.84
Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges. Semin Cancer Biol (2016) 0.83
Impact of Epigenetic Dietary Components on Cancer through Histone Modifications. Curr Med Chem (2015) 0.82
Identification of four potential epigenetic modulators from the NCI structural diversity library using a cell-based assay. J Biomed Biotechnol (2010) 0.82
Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid. J Biol Chem (2013) 0.81
TGF-β: Titan of Lung Fibrogenesis. Curr Enzym Inhib (2010) 0.81
Caspase-3 and caspase-6 cleave STAT1 in leukemic cells. Oncotarget (2014) 0.80
NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity. Evid Based Complement Alternat Med (2011) 0.80
Downregulation of matrix metalloproteinases contributes to the inhibition of cell migration and invasion in HepG2 cells by sodium valproate. Oncol Lett (2015) 0.80
Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibition. J Mol Signal (2009) 0.80
Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine. EPMA J (2015) 0.80
HDAC inhibitor trichostatin A suppresses osteoclastogenesis by upregulating the expression of C/EBP-β and MKP-1. Ann N Y Acad Sci (2011) 0.79
Activation of the intrinsic apoptosis pathway contributes to the induction of apoptosis in hepatocellular carcinoma cells by valproic acid. Oncol Lett (2014) 0.78
Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery. Int J Mol Sci (2011) 0.78
Epigenetics of Stress, Addiction, and Resilience: Therapeutic Implications. Mol Neurobiol (2014) 0.78
Differential effects of binge methamphetamine injections on the mRNA expression of histone deacetylases (HDACs) in the rat striatum. Neurotoxicology (2014) 0.77
Role of Deacetylase Activity of N-Deacetylase/N-Sulfotransferase 1 in Forming N-Sulfated Domain in Heparan Sulfate. J Biol Chem (2015) 0.77
Protein post-translational modifications: In silico prediction tools and molecular modeling. Comput Struct Biotechnol J (2017) 0.75
Dysregulation of Acetylation Enzymes Inanimal Models of Psychostimulant use Disorders: Evolving Stories. Curr Neuropharmacol (2016) 0.75
Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition. Oncogene (2017) 0.75
Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft. Invest New Drugs (2017) 0.75
A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science (1996) 12.64
Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J (2003) 11.27
ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS. Proc Natl Acad Sci U S A (1964) 9.91
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov (2002) 6.97
Acetylation and deacetylation of non-histone proteins. Gene (2005) 6.87
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell (2002) 5.19
The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr (1996) 4.62
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 4.62
Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther (2003) 3.37
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Histone deacetylases, transcriptional control, and cancer. J Cell Physiol (2000) 3.18
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med (2001) 3.07
Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell (2006) 3.07
The human histone deacetylase family. Exp Cell Res (2001) 2.86
Histone deacetylases. Curr Opin Pharmacol (2003) 2.58
Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res (2000) 2.47
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol (2005) 2.29
Histone acetylation and disease. Cell Mol Life Sci (2001) 2.11
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res (2001) 2.08
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene (2002) 2.02
Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem (2001) 1.97
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res (2006) 1.81
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res (2006) 1.67
Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum (2004) 1.67
Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med (2000) 1.56
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res (2007) 1.53
Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res (2004) 1.50
Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res (2007) 1.46
Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs (2002) 1.45
Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res (2003) 1.44
The expression of endothelial nitric-oxide synthase is controlled by a cell-specific histone code. J Biol Chem (2005) 1.44
Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett (2001) 1.44
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res (2007) 1.42
Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol (2004) 1.41
Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res (2002) 1.37
Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med (2000) 1.36
Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun (2003) 1.31
Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene (2004) 1.31
Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol (2001) 1.30
p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene (2003) 1.29
Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res (1994) 1.25
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther (2005) 1.24
Post-transcriptional regulation of endothelial nitric-oxide synthase by an overlapping antisense mRNA transcript. J Biol Chem (2004) 1.22
The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther (2004) 1.22
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene (1999) 1.22
The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol (2005) 1.21
Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis (2004) 1.18
Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res (2000) 1.17
Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia (1999) 1.14
Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer (2002) 1.11
Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis (2006) 1.09
p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep (2005) 1.05
Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett (2002) 1.05
Paradoxical effects of trichostatin A: inhibition of NF-Y-associated histone acetyltransferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA. Cancer Lett (2001) 1.01
Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. J Mol Med (Berl) (2007) 1.01
Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. Cell Signal (2004) 1.01
Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp (2004) 0.99
Functional interplay between modulation of histone deacetylase activity and its regulatory role in G2-M transition. Biochem Biophys Res Commun (2003) 0.99
Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites. Biochem Biophys Res Commun (2006) 0.98
Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol (2003) 0.95
Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun (2004) 0.92
Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells. Int J Oncol (2005) 0.89
Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid (2001) 0.88
Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Chem Biol Interact (2007) 0.86
Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: a potential strategy for uveal melanoma. Melanoma Res (2005) 0.85
Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol (2004) 0.84
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer (2008) 3.04
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther (2002) 2.83
Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies. Hepatology (2013) 2.10
A six-gene signature predicting breast cancer lung metastasis. Cancer Res (2008) 2.09
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene (2002) 2.02
Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer (2008) 1.93
Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J (2005) 1.70
Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate (2012) 1.54
Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation. Prostate (2002) 1.48
Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res (2007) 1.46
Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta (2007) 1.43
Galectin-3 and cancer (Review). Int J Oncol (2004) 1.37
Expression of galectins in cancer: a critical review. Glycoconj J (2004) 1.28
Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene (2004) 1.26
Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am J Pathol (2004) 1.22
Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology (2010) 1.22
Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab Invest (2003) 1.21
A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res (2007) 1.15
Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer (2010) 1.11
Faciogenital dysplasia protein Fgd1 regulates invadopodia biogenesis and extracellular matrix degradation and is up-regulated in prostate and breast cancer. Cancer Res (2009) 1.11
Phenotypic characterization of osteoblasts from the sclerotic zones of osteoarthritic subchondral bone. Arthritis Rheum (2008) 1.09
Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. J Proteome Res (2011) 1.08
Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis. J Natl Cancer Inst (2011) 1.07
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood (2006) 1.04
Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer (2008) 1.03
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone (2010) 1.01
Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. Cancer Res (2011) 1.00
Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatol (2012) 0.96
Runx2- and histone deacetylase 3-mediated repression is relieved in differentiating human osteoblast cells to allow high bone sialoprotein expression. J Biol Chem (2007) 0.95
Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochem J (2004) 0.94
Histone deacetylases: anti-angiogenic targets in cancer therapy. Curr Cancer Drug Targets (2010) 0.94
Revealing the anti-tumoral effect of Algerian Glaucium flavum roots against human cancer cells. Phytomedicine (2013) 0.91
Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage. Eur Urol (2006) 0.89
Expression of dentin sialophosphoprotein in human prostate cancer and its correlation with tumor aggressiveness. Int J Cancer (2006) 0.89
[Histone deacetylases: a new class of efficient anti-tumor drugs]. Med Sci (Paris) (2008) 0.88
Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer (2010) 0.88
The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2. PLoS One (2013) 0.88
Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus. Am J Surg Pathol (2006) 0.87
Myoferlin is a key regulator of EGFR activity in breast cancer. Cancer Res (2013) 0.87
Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. Anticancer Res (2012) 0.85
Metallothionein-dependent up-regulation of TGF-β2 participates in the remodelling of the myxomatous mitral valve. Cardiovasc Res (2011) 0.85
Sparc-like protein 1 is a new marker of human glioma progression. J Proteome Res (2012) 0.84
Selected protein monitoring in histological sections by targeted MALDI-FTICR in-source decay imaging. Anal Chem (2013) 0.84
p53-dependent downregulation of metastasis-associated laminin receptor. Oncogene (2002) 0.84
Identification of accessible human cancer biomarkers using ex vivo chemical proteomic strategies. Expert Rev Proteomics (2007) 0.84
A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. PLoS One (2013) 0.83
The angiogenesis suppressor gene AKAP12 is under the epigenetic control of HDAC7 in endothelial cells. Angiogenesis (2012) 0.82
Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. Neoplasia (2008) 0.82
Differential proteomic analysis of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular proteins associated with bone metastasis. J Proteome Res (2012) 0.82
Histone deacetylases and cancer-associated angiogenesis: current understanding of the biology and clinical perspectives. Crit Rev Oncog (2015) 0.80
A new role for histone deacetylase 5 in the maintenance of long telomeres. FASEB J (2013) 0.79
Novel comprehensive approach for accessible biomarker identification and absolute quantification from precious human tissues. J Proteome Res (2011) 0.79
ΔNp63 isoform-mediated β-defensin family up-regulation is associated with (lymph)angiogenesis and poor prognosis in patients with squamous cell carcinoma. Oncotarget (2014) 0.78
Accessibilome of human glioblastoma: collagen-VI-alpha-1 is a new target and a marker of poor outcome. J Proteome Res (2014) 0.78
Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines. BMC Cancer (2014) 0.77
[SIBLING proteins: molecular tools for tumor progression and angiogenesis]. Med Sci (Paris) (2013) 0.77
Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents. J Pharmacol Exp Ther (2006) 0.76
Identification and quantification of the main active anticancer alkaloids from the root of Glaucium flavum. Int J Mol Sci (2013) 0.76
Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapies. Am J Pathol (2010) 0.76
Isotopically labeled proteome as an internal standard for multiple reaction monitoring-based biomarker quantification. Expert Rev Proteomics (2012) 0.75
S-acetyl-glutathione selectively induces apoptosis in human lymphoma cells through a GSH-independent mechanism. Int J Oncol (2002) 0.75